tracking
Rate this Video

No Evidence of Disease Activity With Ocrelizumab for Multiple Sclerosis

Anthony L. Traboulsee, MD, FRCPC, discusses his research with ocrelizumab for RRMS. The data, which has been called "game changing," was presented at the 2016 American Academy of Neurology Annual Meeting in Vancouver.

To learn more about ocrelizumab and read the full article, go here:
http://www.neurologyadvisor.com/aan-2016-coverage/benefit-of-ocrelizumab-seen-in-ms/article/491125/
Link
Embed
Email
Comments (0)
Add your comment
Advertisement